Renal response to 9 alpha, 11 beta-prostaglandin F2 in the rat

9 alpha, 11 beta-Prostaglandin F2 (9 alpha, 11 beta-PGF2) is a novel PG formed from PGD2 by the action of 11-ketoreductase which has been shown to exist in the liver, lung and kidneys. 9 alpha, 11 beta-PGF2 has been reported to possess platelet antiaggregatory, vasoconstrictor and bronchoconstrictor properties. To define further the biological activity of 9 alpha, 11 beta-PGF2, with respect to kidney function, studies were conducted in anesthetized male Sprague-Dawley rats prepared for renal clearance measurements. Intravenous infusion of highly-purified 9 alpha, 11 beta-PGF2 (2.5 micrograms/min, n = 9) elevated urine flow (28 +/- 6 microliter/min, P less than .05), urinary sodium/potassium (0.96 +/- 0.31, P less than .05), hematocrit (0.5 +/- 0.3, volumes/100 ml, P less than .05) and urinary sodium excretion (2.3 +/- 1.0 microEq/min). Similar responses but of greater magnitude were obtained with PGF2 alpha (2.5 micrograms/min). Glomerular filtration rate (GFR) and mean arterial pressure (MAP) were unaffected. In contrast, PGD2 (2.5 micrograms/min) resulted in decreases in MAP and concomitant reductions in GFR, urine flow and sodium excretion. Abrupt and pronounced increases in urine flow and sodium excretion were observed on administration of 9 alpha, 11 beta-PGF2 at 7.5 micrograms/min. 9 alpha, 11 beta-PGF2 (2.5 micrograms/min) produced consistent increases in urine flow and the excretion of sodium and chloride in rats treated with meclofenamate, 2 mg/kg/hr i.v., indicating that these responses were not dependent on endogenous PG synthesis.(ABSTRACT TRUNCATED AT 250 WORDS)